secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2026-10-16T11:01:22+00:00
Accession:  0001193125-26-423377
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Fractyl's Revita hits REMAIN-1 six-month endpoint, cutting post-GLP-1 weight regain 80% vs 67% sham (p=0.0023)
--------------------------------------------------------------------------------

- Six-month co-primary endpoint met in mITT (N=308): Revita maintained ~80% of GLP-1-induced weight loss vs 67% for sham; mean weight regain 5.1% vs 8.2% (p=0.0023).
- 32% of Revita participants were weight-stable or lost more weight at 6 months post-GLP-1 discontinuation vs 18% for sham (post hoc; nominal p=0.020).
- Dose response: 12-18 cm duodenal ablation cut regain 43% vs sham (4.7% vs 8.2%; n=107); 20 cm or more cut regain 53% (3.8%; n=47).
- Safety: no device- or procedure-related serious adverse events or deaths; no unanticipated device effects at the Sept. 24, 2026 cut-off; 94% of related AEs were within 7 days.
- Plans FDA De Novo submission in late Q4 2026, 12-month data plus second co-primary endpoint in Q1 2027, CPT code 1122T effective Jan 1, 2027, potential U.S. launch early 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526423377/0001193125-26-423377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526423377/guts-20261016.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-423377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer